Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2003024394 - METHODE DE TRAITEMENT D'HYPERPLASIE PROSTATIQUE BENIGNE ET D'AUTRES PATHOLOGIES PROSTATIQUES BENIGNES

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

THE CLAIMS

What is claimed is:
. A method of treatment of benign prostatic hyperplasia comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.

2. The method of Claim 1 wherein said sustaining period is about one year.

3. The method of Claim 1 wherein said initial treatment period is about fourteen days.

4. The method of Claim 1 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.

5. The method of Claim 4 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.

6. A method of reduction of a level of a prostate specific antigen (PSA) of benign prostate conditions comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.

7. The method of Claim 6 wherein said sustaining period is about one year.

8. The method of Claim 6 wherein said initial treatment period is about fourteen days.

9. The method of Claim 6 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.

10. The method of Claim 9 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.